Multicenter clinical trials comparing cefotetan with moxalactam or cefoxitin as therapy for obstetric and gynecologic infections

Richard L. Sweet, Stanley A. Gall, Ronald S. Gibbs, David L. Hemsell, Robert A. Knuppel, Timothy W. Lane, R. David Miller, Edward R. Newton, Alfred N. Poindexter, Wilfred Reguero, Michael Spence, Stanley H. Tschler

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The clinical efficacy and safety of cefotetan was assessed in two multicenter clinical trials involving 335 evaluable patients hospitalized with obstetric and gynecologic infections. In Study I, cefotetan was compared with moxalactam and in Study II, cefotetan was compared with cefoxitin. The clinical response rate in Study I was 67 of 70 patients for cefotetan (96 percent) and 33 of 34 patients (97 percent) for moxalactam. In Study II, the clinical response rate was 138 of 147 patients in the cefotetan group (94 percent) and 76 of 84 patients in the cefoxitin group (91 percent). For the patients with bacteriologic response data, 196 of 205 cefotetan patients (96 percent), 23 of 24 moxalactam patients (96 percent), and 70 of 75 cefoxitin patients (93 percent) had a satisfactory bacteriologic response. Cefotetan was well tolerated and produced no major adverse reactions. The mean amout of cefotetan given was lower than that of moxalactam or cefoxitin.

Original languageEnglish (US)
Pages (from-to)56-60
Number of pages5
JournalThe American Journal of Surgery
Volume155
Issue number5 SUPPL.
DOIs
StatePublished - May 31 1988

Fingerprint

Cefotetan
Moxalactam
Cefoxitin
Obstetrics
Multicenter Studies
Clinical Trials
Infection
Therapeutics

ASJC Scopus subject areas

  • Surgery

Cite this

Multicenter clinical trials comparing cefotetan with moxalactam or cefoxitin as therapy for obstetric and gynecologic infections. / Sweet, Richard L.; Gall, Stanley A.; Gibbs, Ronald S.; Hemsell, David L.; Knuppel, Robert A.; Lane, Timothy W.; Miller, R. David; Newton, Edward R.; Poindexter, Alfred N.; Reguero, Wilfred; Spence, Michael; Tschler, Stanley H.

In: The American Journal of Surgery, Vol. 155, No. 5 SUPPL., 31.05.1988, p. 56-60.

Research output: Contribution to journalArticle

Sweet, RL, Gall, SA, Gibbs, RS, Hemsell, DL, Knuppel, RA, Lane, TW, Miller, RD, Newton, ER, Poindexter, AN, Reguero, W, Spence, M & Tschler, SH 1988, 'Multicenter clinical trials comparing cefotetan with moxalactam or cefoxitin as therapy for obstetric and gynecologic infections', The American Journal of Surgery, vol. 155, no. 5 SUPPL., pp. 56-60. https://doi.org/10.1016/S0002-9610(88)80214-9
Sweet, Richard L. ; Gall, Stanley A. ; Gibbs, Ronald S. ; Hemsell, David L. ; Knuppel, Robert A. ; Lane, Timothy W. ; Miller, R. David ; Newton, Edward R. ; Poindexter, Alfred N. ; Reguero, Wilfred ; Spence, Michael ; Tschler, Stanley H. / Multicenter clinical trials comparing cefotetan with moxalactam or cefoxitin as therapy for obstetric and gynecologic infections. In: The American Journal of Surgery. 1988 ; Vol. 155, No. 5 SUPPL. pp. 56-60.
@article{f3f7e9ecbc9241cda32140e12ec9996a,
title = "Multicenter clinical trials comparing cefotetan with moxalactam or cefoxitin as therapy for obstetric and gynecologic infections",
abstract = "The clinical efficacy and safety of cefotetan was assessed in two multicenter clinical trials involving 335 evaluable patients hospitalized with obstetric and gynecologic infections. In Study I, cefotetan was compared with moxalactam and in Study II, cefotetan was compared with cefoxitin. The clinical response rate in Study I was 67 of 70 patients for cefotetan (96 percent) and 33 of 34 patients (97 percent) for moxalactam. In Study II, the clinical response rate was 138 of 147 patients in the cefotetan group (94 percent) and 76 of 84 patients in the cefoxitin group (91 percent). For the patients with bacteriologic response data, 196 of 205 cefotetan patients (96 percent), 23 of 24 moxalactam patients (96 percent), and 70 of 75 cefoxitin patients (93 percent) had a satisfactory bacteriologic response. Cefotetan was well tolerated and produced no major adverse reactions. The mean amout of cefotetan given was lower than that of moxalactam or cefoxitin.",
author = "Sweet, {Richard L.} and Gall, {Stanley A.} and Gibbs, {Ronald S.} and Hemsell, {David L.} and Knuppel, {Robert A.} and Lane, {Timothy W.} and Miller, {R. David} and Newton, {Edward R.} and Poindexter, {Alfred N.} and Wilfred Reguero and Michael Spence and Tschler, {Stanley H.}",
year = "1988",
month = "5",
day = "31",
doi = "10.1016/S0002-9610(88)80214-9",
language = "English (US)",
volume = "155",
pages = "56--60",
journal = "American Journal of Surgery",
issn = "0002-9610",
publisher = "Elsevier Inc.",
number = "5 SUPPL.",

}

TY - JOUR

T1 - Multicenter clinical trials comparing cefotetan with moxalactam or cefoxitin as therapy for obstetric and gynecologic infections

AU - Sweet, Richard L.

AU - Gall, Stanley A.

AU - Gibbs, Ronald S.

AU - Hemsell, David L.

AU - Knuppel, Robert A.

AU - Lane, Timothy W.

AU - Miller, R. David

AU - Newton, Edward R.

AU - Poindexter, Alfred N.

AU - Reguero, Wilfred

AU - Spence, Michael

AU - Tschler, Stanley H.

PY - 1988/5/31

Y1 - 1988/5/31

N2 - The clinical efficacy and safety of cefotetan was assessed in two multicenter clinical trials involving 335 evaluable patients hospitalized with obstetric and gynecologic infections. In Study I, cefotetan was compared with moxalactam and in Study II, cefotetan was compared with cefoxitin. The clinical response rate in Study I was 67 of 70 patients for cefotetan (96 percent) and 33 of 34 patients (97 percent) for moxalactam. In Study II, the clinical response rate was 138 of 147 patients in the cefotetan group (94 percent) and 76 of 84 patients in the cefoxitin group (91 percent). For the patients with bacteriologic response data, 196 of 205 cefotetan patients (96 percent), 23 of 24 moxalactam patients (96 percent), and 70 of 75 cefoxitin patients (93 percent) had a satisfactory bacteriologic response. Cefotetan was well tolerated and produced no major adverse reactions. The mean amout of cefotetan given was lower than that of moxalactam or cefoxitin.

AB - The clinical efficacy and safety of cefotetan was assessed in two multicenter clinical trials involving 335 evaluable patients hospitalized with obstetric and gynecologic infections. In Study I, cefotetan was compared with moxalactam and in Study II, cefotetan was compared with cefoxitin. The clinical response rate in Study I was 67 of 70 patients for cefotetan (96 percent) and 33 of 34 patients (97 percent) for moxalactam. In Study II, the clinical response rate was 138 of 147 patients in the cefotetan group (94 percent) and 76 of 84 patients in the cefoxitin group (91 percent). For the patients with bacteriologic response data, 196 of 205 cefotetan patients (96 percent), 23 of 24 moxalactam patients (96 percent), and 70 of 75 cefoxitin patients (93 percent) had a satisfactory bacteriologic response. Cefotetan was well tolerated and produced no major adverse reactions. The mean amout of cefotetan given was lower than that of moxalactam or cefoxitin.

UR - http://www.scopus.com/inward/record.url?scp=0023894506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023894506&partnerID=8YFLogxK

U2 - 10.1016/S0002-9610(88)80214-9

DO - 10.1016/S0002-9610(88)80214-9

M3 - Article

C2 - 3287970

AN - SCOPUS:0023894506

VL - 155

SP - 56

EP - 60

JO - American Journal of Surgery

JF - American Journal of Surgery

SN - 0002-9610

IS - 5 SUPPL.

ER -